PIG-Q Activators
PIG-Q Activators are chemical compounds that enhance the functional activity of PIG-Q, a crucial component of the Glycosylphosphatidylinositol (GPI) biosynthetic pathway. These activators exert their influence primarily by modulating the mevalonate pathway, a metabolic pathway thatcontributes critical intermediates for GPI biosynthesis. The mevalonate pathway is central to several biosynthetic processes, including the production of isopentenyl diphosphate (IPP) and farnesyl diphosphate (FPP), which are substrates for the synthesis of dolichol phosphate, an essential component for GPI biosynthesis. PIG-Q activators, such as the bisphosphonates Pamidronic Acid, Zoledronic Acid, Alendronic Acid, Risedronic Acid, and Ibandronic Acid, inhibit the enzyme farnesyl diphosphate synthase, thus increasing the availability of IPP. Similarly, the statins Atorvastatin, Simvastatin, and Lovastatin inhibit the enzyme HMG-CoA reductase, also boosting IPP levels.
Additionally, the farnesyl transferase inhibitors Tipifarnib and Lonafarnib, and the geranylgeranyl transferase inhibitors GGTI-298 and GGTI-2133, function by preventing the conversion of FPP and geranylgeranyl diphosphate (GGPP) respectively into their protein forms. This action increases the availability of these intermediates, which are substrates for the synthesis of dolichol phosphate, thereby indirectly enhancing PIG-Q activity. By increasing the availability of these intermediates, these PIG-Q activators can enhance the GPI biosynthetic pathway, which is crucial for the glycosylation of proteins, a process that facilitates protein stability, trafficking, and function. Thus, through their various modes of action, PIG-Q activators contribute to maintaining and enhancing the function of PIG-Q and the GPI biosynthetic pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic Acid is another bisphosphonate that inhibits farnesyl diphosphate synthase. This action increases the availability of IPP, a substrate for dolichol phosphate synthesis necessary for the GPI pathway in which PIG-Q operates. | ||||||
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
Alendronic Acid is a bisphosphonate that inhibits farnesyl diphosphate synthase, thereby increasing the availability of IPP which is necessary for dolichol phosphate synthesis, a crucial component in the GPI pathway where PIG-Q is active. | ||||||
Ibandronic Acid | 114084-78-5 | sc-207749 | 100 mg | $300.00 | ||
Ibandronic Acid, a bisphosphonate, inhibits farnesyl diphosphate synthase, thus increasing the availability of IPP essential for dolichol phosphate synthesis in the GPI pathway, enhancing PIG-Q activity. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin, a statin, inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This action increases IPP availability, which is necessary for dolichol phosphate synthesis in the GPI pathway where PIG-Q is involved. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, another statin, inhibits HMG-CoA reductase, thereby increasing the availability of IPP, a substrate for dolichol phosphate synthesis in the GPI pathway involving PIG-Q. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, a member of the statin class, inhibits HMG-CoA reductase, increasing the availability of IPP, which is necessary for dolichol phosphate synthesis, a key component of the GPI pathway that involves PIG-Q. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib, a farnesyl transferase inhibitor, can increase the availability of farnesyl diphosphate (FPP) by inhibiting its conversion to farnesyl protein. FPP is a substrate for the synthesis of geranylgeranyl diphosphate (GGPP), which is essential for dolichol phosphate synthesis in the GPI pathway where PIG-Q is involved. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Lonafarnib, another farnesyl transferase inhibitor, can increase the availability of FPP, a substrate for dolichol phosphate synthesis in the GPI pathway, by inhibiting its conversion to farnesyl protein, thereby enhancing PIG-Q activity. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
GGTI-298, a geranylgeranyl transferase inhibitor, can increase the availability of GGPP, a crucial substrate for dolichol phosphate synthesis in the GPI pathway, by inhibiting its conversion to geranylgeranylated protein, thereby enhancing PIG-Q activity. | ||||||
GGTI-2133 | 1217480-14-2 | sc-221668 sc-221668A | 1 mg 5 mg | $219.00 $632.00 | 2 | |
GGTI-2133, another geranylgeranyl transferase inhibitor, can increase the availability of GGPP by inhibiting its conversion to geranylgeranylated protein, enhancing the dolichol phosphate synthesis in the GPI pathway where PIG-Q functions. | ||||||